# Rituximab-abbs

## Truxima inj 500mg/50mL

##### 臨採

| TAH Drug Code      | [ITRU](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ITRU)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | The treatment of adult patients with Non-Hodgkin’s Lymphoma (NHL): Relapsed or refractory, low-grade or follicular, CD20-positive B-cell NHL as a single agent; OR Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; OR Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Chronic lymphoid leukemia: In combination for first-line treatment; OR in combination with fludarabine and cyclophosphamide; OR maintenance, following rituximab-containing chemotherapy. Granulomatosis with polyangiitis or Microscopic polyangiitis: In combination with glucocorticoids                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Dosing             | Recommended Dose for Non-Hodgkin’s Lymphoma (NHL): The recommended dose is 375 mg/m2. Relapsed or Refractory, Low-Grade or Follicular, CD20-Positive, B-Cell NHL: Administer once weekly for 4 or 8 doses. Retreatment for Relapsed or Refractory, Low-Grade or Follicular, CD20Positive, B-Cell NHL: Administer once weekly for 4 doses. Previously Untreated, Follicular, CD20-Positive, B-Cell NHL: Administer on Day 1 of each cycle of chemotherapy, for up to 8 doses. In patients with complete or partial response, initiate TRUXIMA maintenance eight weeks following completion of a rituximab product in combination with chemotherapy. Administer TRUXIMA as a single-agent every 8 weeks for 12 doses. Non-progressing, Low-Grade, CD20-Positive, B-Cell NHL, after first-line CVP chemotherapy: Following completion of 6-8 cycles of CVP chemotherapy, administer once weekly for 4 doses at 6-month intervals to a maximum of 16 doses. First Infusion: Initiate infusion at a rate of 50 mg/hour. In the absence of infusion toxicity, increase infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hour. Subsequent Infusions: Standard Infusion: Initiate infusion at a rate of 100 mg/hour. In the absence of infusion toxicity, increase rate by 100 mg/hour increments at 30-minute intervals, to a maximum of 400 mg/hour. Chronic lymphocytic leukemia: 375 mg/m2 on the day prior to fludarabine/cyclophosphamide in cycle 1, then 500 mg/m2 on day 1 (every 28 days) of cycles 2 to 6 (in combination with fludarabine and cyclophosphamide). Granulomatosis with polyangiitis or microscopic polyangiitis:Induction therapy: 375 mg/m2 once weekly for 4 doses or 1 g once every 2 weeks for 2 doses; for either dosing regimen, administer in combination with a systemic glucocorticoid. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Contraindications  | Hypersensitivity to rituximab and any excipients or proteins in this product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Adverse Effects    | Common Dermatologic: Pruritus (10% to 14% ) Gastrointestinal: Nausea (23% ) Hematologic: Anemia, All Grades (8% to 35% ), Lymphocytopenia, All Grades (48% ) Neurologic: Asthenia (26% ), Headache (19% ) Other: Fever (53% ), Shivering (33% ) Serious Cardiovascular: Cardiogenic shock, Hypotension (10% ), Myocardial infarction, Ventricular fibrillation Dermatologic: Lichen simplex chronicus, Pemphigus paraneoplastica, Stevens-Johnson syndrome, Toxic epidermal necrolysis Gastrointestinal: Gastrointestinal perforation Hematologic: Anemia, Grade 3 or 4 (3% ), Leukopenia, Grade 3 or 4 (4% ), Lymphocytopenia, Grade 3 or 4 (40% ), Neutropenia, Grade 3 or 4 (4% to 6% ), Pancytopenia, Grade 3 or 4, Thrombocytopenia, Grade 3 or 4 (2%) Hepatic: Reactivation of hepatitis B viral hepatitis Neurologic: Progressive multifocal leukoencephalopathy Renal: Nephrotoxicity Respiratory: Bronchospasm (8% ), Pulmonary toxicity (18% ) Other: Angioedema (11% ), Infectious disease (19% to 37% ), Infusion reaction (Equal to or greater than 25% ), Tumor lysis syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

